Delayed
Nasdaq Stockholm
03:01:18 2024-07-12 am EDT
|
5-day change
|
1st Jan Change
|
1.945
SEK
|
-3.71%
|
|
-5.58%
|
-37.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
154.8
|
342.2
|
224.7
|
257
|
193.1
|
173.9
|
-
|
Enterprise Value (EV)
1 |
154.8
|
342.2
|
183
|
257
|
164
|
131.4
|
173.9
|
P/E ratio
|
-3.04
x
|
-4.79
x
|
-2.89
x
|
-3.51
x
|
-
|
6.73
x
|
-1.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
2,898,538
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
2,898,538
x
|
EV / EBITDA
|
-
|
-
|
-2.37
x
|
-
|
-4.34
x
|
-2.83
x
|
-24.8
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
53.6
x
|
7.73
x
|
-2.68
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
1.86%
|
12.9%
|
-37.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,766
|
37,766
|
37,766
|
62,087
|
62,087
|
86,095
|
-
|
Reference price
2 |
4.100
|
9.060
|
5.950
|
4.140
|
3.110
|
2.020
|
2.020
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/24/22
|
2/24/23
|
2/27/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.00006
|
EBITDA
1 |
-
|
-
|
-77.35
|
-
|
-37.79
|
-46.5
|
-7
|
EBIT
1 |
-
|
-
|
-77.93
|
-
|
-38.26
|
-46.5
|
-7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,666,666.67%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-77.78
|
-
|
-37.17
|
-46.5
|
-7
|
Net income
1 |
-50.86
|
-71.37
|
-77.78
|
-56.24
|
-37.17
|
-46.5
|
-7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,666,666.67%
|
EPS
2 |
-1.350
|
-1.890
|
-2.060
|
-1.180
|
-
|
0.3000
|
-1.100
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
3.057
|
17
|
-65
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-108,333,333.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/24/22
|
2/24/23
|
2/27/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
41.7
|
-
|
29.1
|
42.5
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
3.06
|
17
|
-65
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.05
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/24/22
|
2/24/23
|
2/27/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -37.46% | 16.59M | | +20.95% | 127B | | +23.00% | 117B | | +25.47% | 27.77B | | -19.75% | 20.44B | | -15.27% | 16.62B | | -16.56% | 15.92B | | +11.19% | 14.74B | | -46.65% | 14.94B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|